Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04520217 · ClinicalTrials.gov registry record · Phase 1
Testing Use of Topical Imipramine in Reducing Ultraviolet B Induced Microvesicle Particle Release in Photosensitive Subjects
A Phase 1 study of Photosensitivity and Microvesicle Particle, sponsored by Wright State University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT04520217 is a Phase 1 study of Photosensitivity and Microvesicle Particle that is actively recruiting participants, run by Wright State University. The registered enrollment target is 40 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04520217, a Phase 1 study of Photosensitivity and Microvesicle Particle, is actively recruiting participants, sponsored by Wright State University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is three-fold. First, researchers will assess whether subjects who have clinically abnormal reactions to sunlight (photosensitivity) have increased levels of microvesicle particles (MVP) following ultraviolet B (UVB) treatment to localized area of skin. Second, researchers will assess if topical application of the medicine imipramine will block UVB-induced MVP release. Third, researchers will assess if the topical cream will block UVB-induced increased erythema reactions (reddening of the skin).
Conditions Studied
Interventions
- DRUG 4% Imipramine Cream
- DRUG Base Cream
Study Locations (1)
Ohio
- Wright State Physicians - Fairborn
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2022-06-06 |
| Est. Completion | 2026-12-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04520217
The ClinicalTrials.gov registry entry for NCT04520217 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wright State University, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Photosensitivity appearing as the primary indexed condition, and to 2 interventions - of which 4% Imipramine Cream is the first listed.
NCT04520217 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT04520217 about?
NCT04520217 is a clinical study titled "Testing Use of Topical Imipramine in Reducing Ultraviolet B Induced Microvesicle Particle Release in Photosensitive Subjects". The purpose of this study is three-fold. First, researchers will assess whether subjects who have clinically abnormal reactions to sunlight (photosensitivity) have increased levels of microvesicle particles (MVP) following ultraviolet B (UVB) treatment to localized area of skin. Second, researchers ...
What is the current status of trial NCT04520217?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2022-06-06. Estimated completion is 2026-12-01.
What conditions does trial NCT04520217 study?
This clinical trial studies the following conditions: Photosensitivity, Microvesicle Particle.
What interventions are being tested in trial NCT04520217?
The interventions under investigation include: 4% Imipramine Cream (DRUG), Base Cream (DRUG).
Who is sponsoring clinical trial NCT04520217?
This trial is sponsored by Wright State University, which has 32 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04520217 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.